articleJournal of Thrombosis and HaemostasisSep 27, 2007Closed access

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JTJohn T. BrandtSCSandra CloseSJStephen J. IturriaCDChristopher D. PayneNFNazar Farid

Eli Lilly (United States) · Eli Lilly (United Kingdom) · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

729
total citations
FWCI
37.19
Percentile
100%
References
41
Citations per year

Authors

9

Topics & keywords

Topics
Keywords
  • Prasugrel
  • Clopidogrel
  • CYP2C19
  • Pharmacology
  • Pharmacodynamics
  • Active metabolite
  • CYP2C9
  • Ticagrelor
UN Sustainable Development Goals
  • No poverty
No related works found for this paper.